Real-World Evaluation of Prophylactic Anakinra for Toxicity Mitigation in BCMA CAR-T Therapy (IMS 2026) - Sep 11, 2026 - Abstract #PA-395; Pres time: Sep 24, 2026; " This single-center retrospective study included multiple myeloma patients who received idecabtagene vicleucel (ide-cel) therapy...Tocilizumab and dexamethasone intervention was required in 6 (29%), and 8 (38%) patients, respectively... Prophylactic anakinra was well tolerated with a favorable safety profile in multiple myeloma patients receiving BCMA CAR-T therapy. Patients demonstrated manageable rates of severe CRS and ICANS, minimal infection risk, and adequate early cytopenia recovery. Early efficacy was preserved, suggesting anakinra prophylaxis may reduce toxicity without compromising outcomes."
CAR T-Cell Therapy • Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • IL6
|
|
Rishi Nair1; Saranya Gourisetti1; Priyanka Menon1; Anvi Peddi1; Lyle Hickman2; Bryan Locke2; Amany Keruakous2; Anand Jillela2; Yenny Moreno Vanegas2; Shubham Adroja2; Vamsi Kota2
|